[1]
Arjona R, Riancho JA, Aguado JM, Salesa R, González-Macías J. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine. 1995 Jan:74(1):13-23
[PubMed PMID: 7837967]
[2]
Kaya M, Beştaş R, Cetin S. Clinical presentation and management of Fasciola hepatica infection: single-center experience. World journal of gastroenterology. 2011 Nov 28:17(44):4899-904. doi: 10.3748/wjg.v17.i44.4899. Epub
[PubMed PMID: 22171131]
[3]
Soliman MF. Epidemiological review of human and animal fascioliasis in Egypt. Journal of infection in developing countries. 2008 Jun 1:2(3):182-9
[PubMed PMID: 19738348]
Level 2 (mid-level) evidence
[4]
Marcilla A, Bargues MD, Mas-Coma S. A PCR-RFLP assay for the distinction between Fasciola hepatica and Fasciola gigantica. Molecular and cellular probes. 2002 Oct:16(5):327-33
[PubMed PMID: 12477436]
[5]
Hawramy TA, Saeed KA, Qaradaghy SH, Karboli TA, Nore BF, Bayati NH. Sporadic incidence of Fascioliasis detected during hepatobiliary procedures: a study of 18 patients from Sulaimaniyah governorate. BMC research notes. 2012 Dec 21:5():691. doi: 10.1186/1756-0500-5-691. Epub 2012 Dec 21
[PubMed PMID: 23259859]
[6]
Weisenberg SA, Perlada DE. Domestically acquired fascioliasis in northern California. The American journal of tropical medicine and hygiene. 2013 Sep:89(3):588-91. doi: 10.4269/ajtmh.13-0069. Epub 2013 Jul 8
[PubMed PMID: 23836562]
[7]
Mas-Coma S, Valero MA, Bargues MD. Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Advances in parasitology. 2009:69():41-146. doi: 10.1016/S0065-308X(09)69002-3. Epub
[PubMed PMID: 19622408]
Level 3 (low-level) evidence
[8]
Mas-Coma S. Epidemiology of fascioliasis in human endemic areas. Journal of helminthology. 2005 Sep:79(3):207-16
[PubMed PMID: 16153314]
[9]
Bayhan Gİ, Batur A, Taylan-Özkan A, Demirören K, Beyhan YE. A pediatric case of Fascioliasis with eosinophilic pneumonia. The Turkish journal of pediatrics. 2016:58(1):109-112
[PubMed PMID: 27922247]
Level 3 (low-level) evidence
[10]
Al Qurashi H, Masoodi I, Al Sofiyani M, Al Musharaf H, Shaqhan M, All GN. Biliary fascioliasis--an uncommon cause of recurrent biliary colics: report of a case and brief review. German medical science : GMS e-journal. 2012:10():Doc10. doi: 10.3205/000161. Epub 2012 May 2
[PubMed PMID: 22566787]
Level 3 (low-level) evidence
[11]
Prueksapanich P, Piyachaturawat P, Aumpansub P, Ridtitid W, Chaiteerakij R, Rerknimitr R. Liver Fluke-Associated Biliary Tract Cancer. Gut and liver. 2018 May 15:12(3):236-245. doi: 10.5009/gnl17102. Epub
[PubMed PMID: 28783896]
[12]
Tanir G, Karaman A, Tüfekçı SB, Erdoğan D, Tuygun N, Ozkan AT. A case of ectopic intraabdominal fascioliasis presented with acute abdomen. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2011 Jun:22(3):347-50
[PubMed PMID: 21805430]
Level 3 (low-level) evidence
[13]
Kim AJ, Choi CH, Choi SK, Shin YW, Park YK, Kim L, Choi SJ, Han JY, Kim JM, Chu YC, Park IS. Ectopic Human Fasciola hepatica Infection by an Adult Worm in the Mesocolon. The Korean journal of parasitology. 2015 Dec:53(6):725-30. doi: 10.3347/kjp.2015.53.6.725. Epub 2015 Dec 31
[PubMed PMID: 26797440]
[14]
Mas-Coma S, Agramunt VH, Valero MA. Neurological and ocular fascioliasis in humans. Advances in parasitology. 2014:84():27-149. doi: 10.1016/B978-0-12-800099-1.00002-8. Epub
[PubMed PMID: 24480313]
Level 3 (low-level) evidence
[15]
Musa D, Godbole G, Chiodini PL, Phillips R. Unusual case of a lung abscess. BMJ case reports. 2013 Apr 16:2013():. doi: 10.1136/bcr-2012-008306. Epub 2013 Apr 16
[PubMed PMID: 23595175]
Level 3 (low-level) evidence
[16]
Saleha AA. Liver fluke disease (fascioliasis): epidemiology, economic impact and public health significance. The Southeast Asian journal of tropical medicine and public health. 1991 Dec:22 Suppl():361-4
[PubMed PMID: 1822928]
[17]
Cabada MM, White AC Jr. New developments in epidemiology, diagnosis, and treatment of fascioliasis. Current opinion in infectious diseases. 2012 Oct:25(5):518-22. doi: 10.1097/QCO.0b013e3283567b7e. Epub
[PubMed PMID: 22744320]
Level 3 (low-level) evidence
[18]
Espinoza JR, Maco V, Marcos L, Saez S, Neyra V, Terashima A, Samalvides F, Gotuzzo E, Chavarry E, Huaman MC, Bargues MD, Valero MA, Mas-Coma S. Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans. The American journal of tropical medicine and hygiene. 2007 May:76(5):977-82
[PubMed PMID: 17488926]
[19]
Gonzales Santana B, Dalton JP, Vasquez Camargo F, Parkinson M, Ndao M. The diagnosis of human fascioliasis by enzyme-linked immunosorbent assay (ELISA) using recombinant cathepsin L protease. PLoS neglected tropical diseases. 2013:7(9):e2414. doi: 10.1371/journal.pntd.0002414. Epub 2013 Sep 19
[PubMed PMID: 24069474]
[20]
Hassan MM, Saad M, Hegab MH, Metwally S. Evaluation of circulating Fasciola antigens in specific diagnosis of fascioliasis. Journal of the Egyptian Society of Parasitology. 2001 Apr:31(1):271-9
[PubMed PMID: 12557949]
[21]
Santiago N, Hillyer GV. Antibody profiles by EITB and ELISA of cattle and sheep infected with Fasciola hepatica. The Journal of parasitology. 1988 Oct:74(5):810-8
[PubMed PMID: 3138397]
[22]
Shehab AY, Hassan EM, Basha LM, Omar EA, Helmy MH, El-Morshedy HN, Farag HF. Detection of circulating E/S antigens in the sera of patients with fascioliasis by IELISA: a tool of serodiagnosis and assessment of cure. Tropical medicine & international health : TM & IH. 1999 Oct:4(10):686-90
[PubMed PMID: 10583902]
[23]
Prociv P, Walker JC, Whitby M. Human ectopic fascioliasis in Australia: first case reports. The Medical journal of Australia. 1992 Mar 2:156(5):349-51
[PubMed PMID: 1588869]
Level 3 (low-level) evidence
[24]
Sezgin O, Altintaş E, Dişibeyaz S, Saritaş U, Sahin B. Hepatobiliary fascioliasis: clinical and radiologic features and endoscopic management. Journal of clinical gastroenterology. 2004 Mar:38(3):285-91
[PubMed PMID: 15128078]
[25]
Teke M, Önder H, Çiçek M, Hamidi C, Göya C, Çetinçakmak MG, Hattapoğlu S, Ülger BV. Sonographic findings of hepatobiliary fascioliasis accompanied by extrahepatic expansion and ectopic lesions. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2014 Dec:33(12):2105-11. doi: 10.7863/ultra.33.12.2105. Epub
[PubMed PMID: 25425366]
[26]
Koç Z, Ulusan S, Tokmak N. Hepatobiliary fascioliasis: imaging characteristics with a new finding. Diagnostic and interventional radiology (Ankara, Turkey). 2009 Dec:15(4):247-51. doi: 10.4261/1305-3825.DIR.1851-08.2. Epub 2009 Nov 10
[PubMed PMID: 19908182]
[27]
Dias LM, Silva R, Viana HL, Palhinhas M, Viana RL. Biliary fascioliasis: diagnosis, treatment and follow-up by ERCP. Gastrointestinal endoscopy. 1996 Jun:43(6):616-20
[PubMed PMID: 8781945]
[28]
Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001 Jul 1:33(1):1-5
[PubMed PMID: 11389487]
[29]
Villegas F, Angles R, Barrientos R, Barrios G, Valero MA, Hamed K, Grueninger H, Ault SK, Montresor A, Engels D, Mas-Coma S, Gabrielli AF. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano. PLoS neglected tropical diseases. 2012:6(8):e1720. doi: 10.1371/journal.pntd.0001720. Epub 2012 Aug 7
[PubMed PMID: 22880138]
[30]
Keiser J, Sayed H, el-Ghanam M, Sabry H, Anani S, el-Wakeel A, Hatz C, Utzinger J, el-Din SS, el-Maadawy W, Botros S. Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials. PLoS neglected tropical diseases. 2011 Sep:5(9):e1285. doi: 10.1371/journal.pntd.0001285. Epub 2011 Sep 6
[PubMed PMID: 21909440]
[31]
Richter J, Freise S, Mull R, Millán JC. Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole. Tropical medicine & international health : TM & IH. 1999 Nov:4(11):774-81
[PubMed PMID: 10588772]